Heparanase-Neutralizing Monoclonal Antibody (mAb A54) Attenuates Tumor Growth and Metastasis.

Cells · 2025 · PMC12428753 · PMID 40940793

Europe PMC DOI

hedged sentence

0.0050

closest p · 0.1× alpha

0.0050

boldest claim

The sentences

highly significantp < 0.005actually significant

While each drug alone yielded a small effect, the combined (A54 + gemcitabine) treatment yielded a highly significant synergistic inhibition ( p < 0.005) of tumor growth ( Figure 9 ). 3.2.6.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.